Literature DB >> 3280127

Glutamatergic abnormalities in Alzheimer's disease and a rationale for clinical trials with L-glutamate.

S I Deutsch1, J M Morihisa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3280127     DOI： 10.1097/00002826-198802000-00002

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN： 0362-5664            Impact factor:   1.592


× No keyword cloud information.
  6 in total

1.  Aluminum transfer as glutamate complex through blood-brain barrier. Possible implication in dialysis encephalopathy.

Authors:  R Deloncle; O Guillard; F Clanet; P Courtois; A Piriou
Journal:  Biol Trace Elem Res       Date:  1990-04       Impact factor: 3.738

2.  Effects of NMDA receptor antagonists on passive avoidance learning and retrieval in rats and mice.

Authors:  N Venable; P H Kelly
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type.

Authors:  D T Chalmers; D Dewar; D I Graham; D N Brooks; J McCulloch
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

Review 4.  Glutamate: its role in learning, memory, and the aging brain.

Authors:  W J McEntee; T H Crook
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 5.  Mechanism of Alzheimer's disease: arguments for a neurotransmitter-aluminium complex implication.

Authors:  R Deloncle; O Guillard
Journal:  Neurochem Res       Date:  1990-12       Impact factor: 3.996

Review 6.  Neuropathobiology of senile dementia and mechanism of action of nootropic drugs.

Authors:  O Benesová
Journal:  Drugs Aging       Date:  1994-04       Impact factor: 3.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.